Bamboo sure looks good. already in, small position, though. bought IMDS, 0.175 on huge news of cancer treatment. I am wary about most bbs, but this one sounds very good, rising from the bottom of chart on good news accompanied by volume spike.
(COMTEX) B: IMAGING DIAGNOSTIC SYSTEMS RECEIVES PATENT FOR LASER IMAG
B: IMAGING DIAGNOSTIC SYSTEMS RECEIVES PATENT FOR LASER IMAGING APPARATUS USING
'BIOMEDICAL MARKERS' THAT BIND TO CANCER CELLS
FORT LAUDERDALE, Fla., Sep 13, 1999 /PRNewswire via COMTEX/ --
Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) announced
today that their patent application for the laser imaging apparatus
using biomedical markers that bind to cancer cells has received issue
notification from the United States Department of Commerce, Patent and
Trademark office. The patent will be issued September 14, 1999, as
Patent No. 5,952,664.
A "fluorescent marker" is a chemical compound that allows light to be
absorbed at specific locations to locate cancerous tissues. The
fluorescent marker is designed to have a high specificity for cancer
cells. When exposed to light at a specific wavelength, the fluorescent
marker will "glow" at a unique wavelength allowing it to be easily
differentiated from normal tissue. The fluorescence CTLM(TM) scanner
will use this effect to localize the cancerous tissue.
"Fluorescence Markers" is a compound that the Company is currently
studying in conjunction with major pharmaceutical companies as an
advanced diagnostic feature to be used with the Company's laser
mammography system: The CTLM(TM) in combination with the fluorescent
feature has the potential to be used with photodynamic therapy (PDT) to
aid in the treatment of breast cancer.
Imaging Diagnostics' CTLM(TM) is currently in the second series of the
investigational clinical trials at Nassau County Medical Center. This
study involves 275 patients as part of the data required for the
submission to the FDA for marketing approval.
This release may contain forward-looking statements with the meanings
of Section 27A of the Securities Act of 1933 and section 21E of the
Securities Exchange Act of 1934. Actual results and events could differ
materially from those projected as a result of the "known
uncertainties" set forth in detail in the Company's filings with the
Securities and Exchange Commission.
SOURCE Imaging Diagnostic Systems, Inc.
(C) 1999 PR Newswire. All rights reserved.
prnewswire.com -0-
CONTACT: Deborah O'Brien of Imaging Diagnostic Systems, Inc.,
954-581-9800
WEB PAGE: imds.com
GEOGRAPHY: Florida
INDUSTRY CODE: MTC
*** end of story ***
(COMTEX) B: IMAGING DIAGNOSTIC SYSTEMS RECEIVES PATENT FOR LASER IMAG
B: IMAGING DIAGNOSTIC SYSTEMS RECEIVES PATENT FOR LASER IMAGING APPARATUS USING
'BIOMEDICAL MARKERS' THAT BIND TO CANCER CELLS
FORT LAUDERDALE, Fla., Sep 13, 1999 /PRNewswire via COMTEX/ --
Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) announced
today that their patent application for the laser imaging apparatus
using biomedical markers that bind to cancer cells has received issue
notification from the United States Department of Commerce, Patent and
Trademark office. The patent will be issued September 14, 1999, as
Patent No. 5,952,664.
A "fluorescent marker" is a chemical compound that allows light to be
absorbed at specific locations to locate cancerous tissues. The
fluorescent marker is designed to have a high specificity for cancer
cells. When exposed to light at a specific wavelength, the fluorescent
marker will "glow" at a unique wavelength allowing it to be easily
differentiated from normal tissue. The fluorescence CTLM(TM) scanner
will use this effect to localize the cancerous tissue.
"Fluorescence Markers" is a compound that the Company is currently
studying in conjunction with major pharmaceutical companies as an
advanced diagnostic feature to be used with the Company's laser
mammography system: The CTLM(TM) in combination with the fluorescent
feature has the potential to be used with photodynamic therapy (PDT) to
aid in the treatment of breast cancer.
Imaging Diagnostics' CTLM(TM) is currently in the second series of the
investigational clinical trials at Nassau County Medical Center. This
study involves 275 patients as part of the data required for the
submission to the FDA for marketing approval.
This release may contain forward-looking statements with the meanings
of Section 27A of the Securities Act of 1933 and section 21E of the
Securities Exchange Act of 1934. Actual results and events could differ
materially from those projected as a result of the "known
uncertainties" set forth in detail in the Company's filings with the
Securities and Exchange Commission.
SOURCE Imaging Diagnostic Systems, Inc.
(C) 1999 PR Newswire. All rights reserved.
prnewswire.com -0-
CONTACT: Deborah O'Brien of Imaging Diagnostic Systems, Inc.,
954-581-9800
WEB PAGE: imds.com
GEOGRAPHY: Florida
INDUSTRY CODE: MTC
*** end of story *** |
